Induction chemo beneficial in locally advanced pancreatic CA

Share this article:
Induction Chemo Beneficial in Locally Advanced Pancreatic CA
Induction Chemo Beneficial in Locally Advanced Pancreatic CA

(HealthDay News) -- For most patients with locally advanced pancreatic carcinoma (LAPC), induction with a combination of gemcitabine and oxaliplatin (GEMOX) followed by chemoradiotherapy (CRT) is feasible, resulting in clinical benefit, a chance of resectability, and improved survival, according to a study published online July 6 in Cancer.

Francesco Leone, M.D., of the University of Turin in Candiolo, Italy, and colleagues conducted a single-institution study involving 39 patients with LAPC who were treated with GEMOX induction, followed by gemcitabine twice weekly, with concurrent radiotherapy for those who did not progress.

The researchers found that induction and maintenance treatments were well tolerated. Twenty-nine patients obtained disease control, two progressed after GEMOX induction therapy, and a further seven patients progressed after CRT. Median progression-free survival (PFS) at a median of 13 months of follow-up was 10.2 months, but varied from 9.1 months in those with unresectable disease to 16.6 months in those who were borderline resectable (P = 0.056). The median overall survival was 16.7 months, ranging from 13.3 for patients with unresectable disease to 27.8 for those with borderline resectable disease (P = 0.045). Following treatment, 11 patients were able to undergo a successful resection; this was associated with significantly improved PFS (19.7 versus 7.6 months) and median overall survival (31.5 versus 12.3 months), compared with nonresected patients.

"In conclusion, a regimen of induction chemotherapy with GEMOX followed by gemcitabine-based CRT for LAPC is feasible and well tolerated," the authors write. "A high disease control rate and clinical benefit are achievable in most patients."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.